The AST and ALT levels in the LPs group, however, significantly decreased (p < 0.05), suggesting that the effect of NAFLD on the liver was somewhat mitigated by the peptides. The gene discussed is GPT; the disease is metabolic dysfunction-associated steatotic liver disease.